Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis

References

• Matucci-Cerinic M, Miniati I, Denton CP. Eular compendium on rheumatic diseases. In: Bijlsman JWJ, editor. Systemic Sclerosis. 2009:290–296.
   Google Scholar
• Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897–1905. doi:10.1136/annrheumdis-2017-211448
   PubMed Web of Science ®Google Scholar
• McMahan ZH, Volkmann ER. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opin Pharmacother. 2020;21(16):2041–2056. doi:10.1080/14656566.2020.1793960
   PubMed Web of Science ®Google Scholar
• Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology. 2012;51(6):1017–1026. doi:10.1093/rheumatology/ker269
   PubMed Web of Science ®Google Scholar
• Topal AA, Dhurat RS. Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int. 2013;33(1):1–18.
   PubMed Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–1815. doi:10.1136/ard.2009.114264
   PubMed Web of Science ®Google Scholar
• Fransen J, Popa-Diaconi D, Hesselstrand R, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis. 2011;70(10):1788–1792. doi:10.1136/ard.2010.144360
   PubMed Web of Science ®Google Scholar
• Domsic RT, Medsger TA Jr. Connective tissue disease: predicting death in SSc: planning and cooperation are needed. Nat Rev Rheumatol. 2011;7(11):628–630. doi:10.1038/nrrheum.2011.152
   Web of Science ®Google Scholar
• Tyndall A. Hematopoietic stem cell transplantation for systemic sclerosis: review of current status. BioDrugs. 2019;33(4):401–409. doi:10.1007/s40259-019-00364-3
   PubMed Web of Science ®Google Scholar
• Marmont AM. Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol. 2004;17(2):223–232. doi:10.1016/j.beha.2004.04.004
   PubMed Web of Science ®Google Scholar
• Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis. 2001;60(6):577–584. doi:10.1136/ard.60.6.577
   PubMed Web of Science ®Google Scholar
• Farge D, Marolleau JP, Zohar S, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre Phase I-II study. Br J Haematol. 2002;119(3):726–739. doi:10.1046/j.1365-2141.2002.03895.x
   PubMed Web of Science ®Google Scholar
• Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis. 2004;63(8):974–981. doi:10.1136/ard.2003.011205
   PubMed Web of Science ®Google Scholar
• Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007;110(4):1388–1396. doi:10.1182/blood-2007-02-072389
   PubMed Web of Science ®Google Scholar
• Oyama Y, Barr WG, Statkute L, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant. 2007;40(6):549–555. doi:10.1038/sj.bmt.1705782
   Web of Science ®Google Scholar
• Burt RK, Shah S, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised Phase 2 trial. Lancet. 2011;378(9790):498–506. doi:10.1016/S0140-6736(11)60982-3
   PubMed Web of Science ®Google Scholar
• Van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490–2498. doi:10.1001/jama.2014.6368
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35–47. doi:10.1056/NEJMoa1703327
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. doi:10.1136/annrheumdis-2016-209909
   PubMed Web of Science ®Google Scholar
• Farge D, Burt RK, Oliveira MC, et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for blood and marrow transplantation autoimmune diseases working party and collaborating partners. Bone Marrow Transplant. 2017;52(11):1495–1503. doi:10.1038/bmt.2017.56
   PubMed Web of Science ®Google Scholar
• Snowden JA, Saccard R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for blood and marrow transplantation. Bone Marrow Transplant. 2012;47(6):770–790. doi:10.1038/bmt.2011.185
   PubMed Web of Science ®Google Scholar
• Snowden JA, Sharrack B, Akil M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist. Clin Med. 2018;18(4):329–334. doi:10.7861/clinmedicine.18-4-329
   Web of Science ®Google Scholar
• McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood. 2002;100(5):1602–1610. doi:10.1182/blood.V100.5.1602.h81702001602_1602_1610
   PubMed Web of Science ®Google Scholar
• Henes CJ, Koetter I, Horger M, et al. Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology. 2014;53(5):919–922. doi:10.1093/rheumatology/ket464
   Web of Science ®Google Scholar
• Burt RK, Farge D. Autologous HSCT is efficacious, but can we make it safer? Nat Rev Rheumatol. 2018;14(4):189–191. doi:10.1038/nrrheum.2018.34
   Web of Science ®Google Scholar
• Martínez C, Urbano-Ispizua A, Rozman C, et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol. 1999;27(3):561–568. doi:10.1016/S0301-472X(98)00029-0
   Web of Science ®Google Scholar
• Kohno K, Nagafuji K, Tsukamoto H, et al. Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Transpl Infect Dis. 2009;11(4):318–323. doi:10.1111/j.1399-3062.2009.00401.x
   PubMed Web of Science ®Google Scholar
• Oliveira MC, Labopin M, Henes J, et al. Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant. 2016;51(4):501–505. doi:10.1038/bmt.2015.299
   Web of Science ®Google Scholar
• Ayano M, Tsukamoto H, Mitoma H, et al. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan. Arthritis Res Ther. 2019;21(1):30. doi:10.1186/s13075-019-1823-0
   Web of Science ®Google Scholar
• Henes J, Oliveira MC, Lapobin M, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for blood and marrow transplantation autoimmune disease working party. Haematologica. 2021;106(2):375–383. doi:10.3324/haematol.2019.230128
   Web of Science ®Google Scholar
• Henes JC, Schmalzing M, Vogel W, et al. Optimization of autologous stem cell transplantation for systemic sclerosis- a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol. 2012;39(2):269–275. doi:10.3899/jrheum.110868
   Web of Science ®Google Scholar
• Burt RK, Oliveira MC, Shah S, et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet. 2013;381(9872):1116–1124. doi:10.1016/S0140-6736(12)62114-X
   PubMed Web of Science ®Google Scholar
• Helbig G, Widuchowska M, Koglega A, et al. Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis. Clin Rheumatol. 2018;37(6):1709–1714. doi:10.1007/s10067-017-3954-5
   Web of Science ®Google Scholar
• Nakamura H, Odani T, Yasuda S, et al. Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: long-term follow-up on a Phase II trial and treatment- related fatal cardiomyopathy. Mod Rheumatol. 2018;28(5):879–884. doi:10.1080/14397595.2017.1416920
   PubMed Web of Science ®Google Scholar
• Guillaine-Jugnot P, Badoglio M, Labopin M, et al. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Clin Rheumatol. 2019;38(5):1501–1511. doi:10.1007/s10067-019-04435-2
   Web of Science ®Google Scholar
• van Bijnen S, Vries-Bouwstra J, van den Ende CH, et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Ann Rheum Dis. 2020;79(8):1084–1089. doi:10.1136/annrheumdis-2020-217058
   Web of Science ®Google Scholar
• Henrique-Neto A, Vanconcelos MYK, Dias JBE, et al. Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience. Adv Rheumatol. 2021;61(1):9. doi:10.1186/s42358-021-00166-8
   Google Scholar
• Del Papa N, Onida F, Zaccara E, et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant. 2017;52(1):53–58. doi:10.1038/bmt.2016.211
   PubMed Web of Science ®Google Scholar
• Burt RK, Oliveira MC, Shah SJ. Cardiac assessment before stem cell transplantation for systemic sclerosis. JAMA. 2014;312(17):1803. doi:10.1001/jama.2014.12566
   Web of Science ®Google Scholar
• Burt RK, Shah SJ, Gheorghiade M, Ruderman E, Schroeder J. Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: “it is a matter of the heart”. J Rheumatol. 2012;39(2):206–209. doi:10.3899/jrheum.111302
   Web of Science ®Google Scholar
• Hosing C, Nash R, McSweeney P, et al. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. Biol Blood Marrow Transplant. 2011;17(5):674–681. doi:10.1016/j.bbmt.2010.08.003
   Web of Science ®Google Scholar
• Craciunescu OI, Steffey BA, Kelsey CR, et al. Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial. Int J Radiat Oncol Biol Phys. 2011;79(4):1248–1255. doi:10.1016/j.ijrobp.2010.05.036
   Web of Science ®Google Scholar
• Dhesi S, Chu MP, Blevings G, et al. Cyclophosphamide- induced cardiomyopathy: a case report, review and recommendations for management. J Investig Med High Impact Case Rep. 2013;1(1):2324709613480346.
   Google Scholar
• Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 2010;69(1):218–221. doi:10.1136/ard.2008.103382
   PubMed Web of Science ®Google Scholar
• Sandmeier B, Jäger VK, Nagy G, et al. Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. Clin Exp Rheumatol. 2015;33(4 Suppl 91):S75–S79.
   PubMed Web of Science ®Google Scholar
• Burt RK, Han X, Quigley K, et al. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days. Bone Marrow Transplant. 2021;56(1):50–59. doi:10.1038/s41409-020-0978-2
   Web of Science ®Google Scholar
• Snowden JA, Badoglio M, Labopin M, et al.; for European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP); EBMT Paediatric Working Party (PWP); Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT); EBMT (JACIE). Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 2017;1(27):2742–2755. doi:10.1182/bloodadvances.2017010041.
   PubMed Web of Science ®Google Scholar
• Farge D, Lapobin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010;95(2):284–292. doi:10.3324/haematol.2009.013458
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9
   PubMed Web of Science ®Google Scholar
• Spierings J, van Rhenen A, Welsing PM, et al. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open. 2021;11(3):e044483. doi:10.1136/bmjopen-2020-044483
   Web of Science ®Google Scholar
• Ait Abdallah N, Wang M, Lansiaux P, et al. Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score. Bone Marrow Transplant. 2021;56(9):2259–2267. doi:10.1038/s41409-021-01355-1
   Web of Science ®Google Scholar
• Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum. 2000;43(11):2445–2454. doi:10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Costa-Pereira KR, Guimaraes AL, Moraes DA, et al. Hematopoietic stem cell transplantation improves functional outcomes of systemic sclerosis patients. J Clin Rheumatol. 2020;26(7SSuppl 2):S131–S138. doi:10.1097/RHU.0000000000001117
   Web of Science ®Google Scholar
• Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2(1):11–18. doi:10.5301/jsrd.5000231
   PubMed Web of Science ®Google Scholar
• Daikeler T, Kump E, Stern M, et al. Autologous hematopoietic stem cell transplantation reverses skin fibrosis but does not change skin vessel density in patients with systemic sclerosis. Pathol Biol. 2015;63(4–5):164–168. doi:10.1016/j.patbio.2015.07.006
   Google Scholar
• Wada DT, Almeida FA, Moraes DA, et al. Automatic quantitative computed tomography evaluation of the lungs in patients with systemic sclerosis treated with autologous stem cell transplantation. J Clin Rheumatol. 2020;26(7s Suppl 2):S158–S164. doi:10.1097/RHU.0000000000001242
   Web of Science ®Google Scholar
• Kloth C, Thaiss WM, Preibsch H, et al. Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests. Rheumatology. 2016;55(10):1763–1770. doi:10.1093/rheumatology/kew259
   Web of Science ®Google Scholar
• Ciaff J, van Leeuwen NM, Boonstra M, et al. Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. Arthritis Care Res. 2020. doi:10.1002/acr.24451
   Web of Science ®Google Scholar
• Maltez N, Puyade M, Wang M, et al. Association of autologous hematopoietic stem cell transplantation in systemic sclerosis with marked improvement in health-related quality of life. Arthritis Rheumatol. 2021;73(2):305–314. doi:10.1002/art.41519
   Web of Science ®Google Scholar
• Puyade M, Maltez N, Lansiaux P, et al. Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant- a systematic review. Rheumatology. 2020;59(4):779–789. doi:10.1093/rheumatology/kez300
   Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Fertility and pregnancy outcomes in women with systemic sclerosis. Arthritis Rheum. 1999;42(4):763–768. doi:10.1002/1529-0131(199904)42:4<763::AID-ANR21>3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Taborelli M, Ramoni V, Brucato A, et al. Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. Arthritis Rheum. 2012;64(6):1970–1977. doi:10.1002/art.34350
   Web of Science ®Google Scholar
• Harward LE, Mitchell K, Pieper C, Copland S, Criscione-Schreiber LG, Clowse ME. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus. 2013;22(1):81–86. doi:10.1177/0961203312468624
   PubMed Web of Science ®Google Scholar
• Nowlin NS, Brick JE, Weaver DJ, et al. Impotence in scleroderma. Ann Intern Med. 1986;104(6):794–798. doi:10.7326/0003-4819-104-6-794
   Web of Science ®Google Scholar
• Krittian SM, Saur SJ, Schloegl A, et al. Erectile function and connective tissue diseases. Prevalence of erectile dysfunction in German men with systemic sclerosis compared to other connective tissue diseases and healthy subjects. Clin Exp Rheumatol. 2021;39(Suppl 131):52–56.
   Google Scholar
• Snarski E, Snowden JA, Oliveira MC, et al. Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune disease: a retrospective study of the EBMT aUtoimmune Diseases Working Party (ADWP). Bone Marrow Transplant. 2015;50(2):216–220. doi:10.1038/bmt.2014.248
   Web of Science ®Google Scholar
• Massenkeil G, Alexander T, Rosen O, et al. Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation. Rheumatol Int. 2016;36(11):1563–1568. doi:10.1007/s00296-016-3531-2
   PubMed Web of Science ®Google Scholar
• Somers EC, Thomas SL, Smeeth L, Hall AJ. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am J Epidemiol. 2009;169(6):749–755. doi:10.1093/aje/kwn408
   PubMed Web of Science ®Google Scholar
• Daikler T, Labopin M, Di Gioia M, et al. Secondary autoimmune disease occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT autoimmune disease working party. Blood. 2011;118(6):1693–1698. doi:10.1182/blood-2011-02-336156
   Web of Science ®Google Scholar
• Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913–1921. doi:10.1002/art.37969
   PubMed Web of Science ®Google Scholar
• Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J. 2008;101(1):59–62. doi:10.1097/SMJ.0b013e31815838ce
   PubMed Web of Science ®Google Scholar
• Franks JM, Martyanov V, Wang Y, et al. Machine learning predicts stem cell transplant response in severe scleroderma. Ann Rheum Dis. 2020;79(12):1608–1615. doi:10.1136/annrheumdis-2020-217033
   PubMed Web of Science ®Google Scholar
• Showalter K, Spiera R, Magro C, et al. Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarization as a hallmark of clinical severity and improvement. Ann Rheum Dis. 2021;80(2):228–237. doi:10.1136/annrheumdis-2020-217840
   Web of Science ®Google Scholar
• EBMT ADWP prospective non-interventional Study: post-AHSCT management in SSC patients (NISSC-2). Available from: https://clinicaltrials.gov/ct2/show/NCT03444805. NLM identifier: NCT03444805. Accessed September 6, 2021.
   Google Scholar
• Scleroderma Treatment With Autologous Transplant (STAT) Study. Available from: https://clinicaltrials.gov/ct2/show/NCT01413100. NLM identifier: NCT01413100. Accessed September 6, 2021.
   Google Scholar
• Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33–46. doi:10.1007/s13238-016-0323-0
   PubMed Web of Science ®Google Scholar
• Palchaudhuri R, Saez B, Hoggatt J, et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol. 2016;34(7):738–745. doi:10.1038/nbt.3584
   Web of Science ®Google Scholar